As reported on PharmaBiz, the U.S. Food and Drug Administration has accepted Takeda’s New Drug Application for the investigational oral therapy zasocitinib (TAK-279) and assigned the filing Priority Review status for the treatment of adults with moderate-to-severe plaque psoriasis. The move marks a significant regulatory milestone for the selective tyrosine kinase 2 (TYK2) inhibitor, which is being developed as a once-daily oral treatment option for patients with chronic inflammatory skin disease.
According to Takeda, the application is backed by data from a broad clinical development program involving nearly 3,000 patients. Results from the pivotal phase 3 LATITUDE PsO 3001 and 3002 studies showed that the therapy met all primary and key secondary endpoints, demonstrating meaningful improvements in skin clearance and symptoms.
In the phase 3 trials, approximately 70% of patients treated with zasocitinib achieved clear or almost clear skin, as measured by static Physician’s Global Assessment (sPGA 0/1), at 16 weeks. Investigators also reported that clinical benefits emerged quickly, with improvements observed as early as four weeks after treatment initiation. Response rates continued to improve through 24 weeks and were maintained through one year of follow-up.
Notably, the therapy demonstrated effectiveness in areas that are often difficult to manage, including the scalp, nails, palms, and soles. These sites can have an outsized impact on daily activities and quality of life despite representing a relatively small body surface area.
Safety findings from the phase 3 program were consistent with previous studies. Takeda reported that zasocitinib was generally well tolerated, and no new safety concerns were identified during the trials. Additional long-term data were provided through the open-label phase 3 LATITUDE PsO 3003 study, which is assessing safety, tolerability, and efficacy over extended treatment periods.
The regulatory momentum extends beyond the United States. The European Medicines Agency has also accepted Takeda’s marketing authorization application for zasocitinib, initiating formal review in the European Union. The company plans to pursue additional submissions in other regions as it seeks global approvals.
Plaque psoriasis accounts for the vast majority of psoriasis cases worldwide. The immune-mediated disease is associated with chronic inflammation, painful and itchy skin lesions, and substantial physical and psychological burden. Visible involvement of areas such as the scalp and hands, along with common comorbidities such as psoriatic arthritis, can significantly affect quality of life.
Zasocitinib is designed to selectively inhibit TYK2, a signaling molecule involved in key inflammatory pathways implicated in psoriasis, including the IL-23/IL-17 axis and type I interferon signaling. Unlike broader Janus kinase (JAK) inhibitors, the agent was engineered to target TYK2 with high specificity, potentially limiting effects on related JAK pathways involved in other biological processes.
Beyond psoriasis, Takeda is studying zasocitinib in several immune-mediated diseases. Ongoing clinical programs include phase 3 evaluation in psoriatic arthritis and phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.
If approved, zasocitinib could expand the range of oral treatment options available for patients with moderate-to-severe plaque psoriasis, offering a potential alternative for those seeking durable skin clearance without injectable therapy.
